Cost-effectiveness of current and optimal treatment for schizophrenia

British Journal of Psychiatry

Volumn 183, Issue NOV., 2003, Pages 427-435

  Andrews, Gavin ^a,c   Sanderson, Kristy ^a   Corry, Justine ^a   Issakidis, Cathy ^a   Lapsley, Helen ^b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c Clin Res U for Anxiety Disorders   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT;

ARTICLE; BEHAVIOR THERAPY; COGNITIVE THERAPY; COST EFFECTIVENESS ANALYSIS; DISABILITY; FAMILY COUNSELING; HEALTH CARE COST; HOSPITAL ADMISSION; HUMAN; PRACTICE GUIDELINE; SCHIZOPHRENIA; SOCIAL ADAPTATION;

AGED; COST OF ILLNESS; COST-BENEFIT ANALYSIS; EVIDENCE-BASED MEDICINE; FINANCING, ORGANIZED; HUMANS; MENTAL HEALTH SERVICES; PREVALENCE; PSYCHOTHERAPY; QUALITY-ADJUSTED LIFE YEARS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0242351741     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.183.5.427     Document Type: Article

References (38)

1. Ad Hoc Committee on Health Research Relating to Future Intervention Options (1996) Investing in Health Research and Development. Geneva: World Health Organization.
2. Andrews, G., Hall, W., Goldstein, G., et al (1985) The economic cost of schizophrenia. Archives of General Psychiatry, 42, 537-543.
3. _, Sanderson, K., Corry, J., et al (2000) Using epidemiological data to model efficiency in reducing the burden of depression. Journal of Mental Health Policy and Economics, 3, 175-186.
4. _, Issakidis, C. & Carter, G. (2001) Shortfall in mental health service utilisation. British Journal of Psychiatry, 179, 417-425.
5. _, Slade, T. & Issakidis, C. (2002) Deconstructing current comorbidity: data from the Australian National Survey of Mental Health and Well-Being. British Journal of Psychiatry, 181, 306-314.
6. Australian Bureau of Statistics (1998) Average Weekly Earnings, Publication No. 6302.0. Canberra: Australian Bureau of Statistics.
7. Bijl R. V., Ravelli, A. & van Zessen, G. (1998) Prevalence of psychiatric disorder in the general population: results of The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Social Psychiatry and Psychiatric Epidemiology, 33, 587-595.
8. Carr, V. J., Neil, A. L., Halpin, S. A., et al (2003) Costs of schizophrenia and other psychoses in urban Australia: findings from the Low Prevalence (Psychotic) Disorders study. Australian and New Zealand Journal of Psychiatry, 37, 31-40.
9. Chouinard, G. & Albright, P. S. (1997) Economic and health state utility determinations for schizophrenia patients treated with risperidone or haloperidol. Journal of Clinical Psychopharmacology, 17, 298-307.
10. Conley, R. R. & Kelly, D. L. (2001) Management of treatment resistance in schizophrenia. Biological Psychiatry, 50, 898-911.
11. Crowther, R. E., Marshall, M., Bond, G. R., et al (2001) Helping people with severe mental illness to obtain work: systematic review. BMJ, 3221, 204-208.
12. Geddes, J., Freemantle, N., Harrison, P., et al (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ, 321, 1371-1376.
13. Gold, M. R., Siegel, J. E., Russell, L. B., et al (1996) Cost-effectiveness in Health and Medicine. New York: Oxford University Press.
14. Jablensky, A., McGrath, J., Herrman, H., et al (2000) Psychotic disorders in urban areas: an overview of the Study on Low Prevalence Disorders. Australian and New Zealand Journal of Psychiatry, 34, 221-236.
15. Jones, C., Cormac, I., Mota, J., et al (2000) Cognitive behaviour therapy for schizophrenia. Cochrone Library, issue 2. Oxford: Update Software.
16. Kirsch, I. & Sapirstein, G. (1998) Listening to prozac but hearing placebo: a meta-analysis of antidepressant medication. Prevention & Treatment, I, Article 0002a. http:// Journals.apa.org/prevention/volumeI/ pre0010002a. html
17. Lehman, A. F. & Steinwachs, D. M. (1998) Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophrenia Bulletin, 24, 1-10.
18. Leucht, S., Pitschel-Walz, G., Abraham, D., et al (1999) Efficacy and extrapyrimidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research, 35, 51-68.
19. Link, B. & Dohrenwend, B. P. (1980) Formulation of hypotheses about the ratio of untreated to treated cases in the true prevalence studies of functional psychiatric disorders in adults in the United States. In Mental Illness in the United States: Epidemiological Estimates (eds B. P. Dohrenwend, B. S. Dohrenwend, M. S. Gould, et al). New York: Praeger.
20. Manderscheid, R. W., Rae, D. S., Narrow, W. E., et al (1993) Congruence of service utilization estimates from the Epidemiologic Catchment Area Project and other sources. Archives of General Psychiatry, 50, 108-114.
21. Marshall, T. & Rouse, A. (2002) Resource implications and health benefits of primary prevention strategies for cardiovascular disease in people aged 30-74. BMJ, 325, 197-203.
22. Mason, J., Freemantle, N., Nazareth, I., et al (2001) When is it cost-effective to change the behavior of health professionals? JAMA, 286, 2988-2992.
23. McGlashan, T. H. & Johannessen, J. O. (1996) Early detection and intervention with schizophrenia: rationale. Schizophrenia Bulletin, 22, 201-222.
24. Melse, J. M., Essink-Bot, M.-L., Kramers, P. G. N., et al (2000) A national burden of disease calculation: Dutch disability-adjusted life-years. American Journal of Public Health, 90, 1241-1247.
25. Milner, K. K. & Valenstein, M. (2002) A comparison of guidelines for the treatment of schizophrenia. Psychiatric Services, 53, 888-890.
26. Mojtabai, R., Nicholson, R. A. & Carpenter, B. N. (1998) Role of psychosocial treatments in management of schizophrenia: a meta-analytic review of controlled outcome studies. Schizophrenia Bulletin, 24, 569-587.
27. Musgrove, P. (1999) Public spending on health care: how are the different criteria related? Health Policy, 47, 207-223.
28. Nathan, P. E. & Gorman, J. M. (1996) A Guide to Treatments that Work. New York: Oxford University Press.
29. Pilling, S., Bebbington, P., Kuipers, E., et al (2002) Psychological treatments in schizophrenia: II. Meta-analyses of randomized controlled trials of social skills training and cognitive remediation. Psychological Medicine, 32, 783-791.
30. Quality Assurance Project (1984) Treatment outlines for the management of schizophrenia. Australian and New Zealand Journal of Psychiatry, 18, 19-38.
31. Sanderson, K. & Andrews, G. (2001) Mental disorders and burden of disease: how was disability estimated and is it valid? Australian and New Zealand Journal of Psychiatry, 35, 668-676.
32. Skelton, J. A., Pepe, M. M. & Pineo, T. S. (1995) How much better is clozapine? A meta-analytic review and critical appraisal. Experimental and Clinical Psychopharmacology, 3, 270-279.
33. Smith, G. R., Jr., Manderscheid, R. W., Flynn, L. M., et al (1997) Principles of assessment of patient outcomes in mental health care. Psychiatric Services, 48, 1033-1036.
34. Stouthard M. E. A., Essink-Bot M.-L., Bonsel G. J., et al (1997) Disability Weights for Diseases in The Netherlands. Rotterdam: Department of Public Health, Erasmus University.
35. Thornicroft, G., Becker, T., Holloway, F., et al (1999) Community mental health teams: evidence or belief? British Journal of Psychiatry, 175, 508-513.
36. Warner, R. (2001) The prevention of schizophrenia: what interventions are safe and effective? Schizophrenia Bulletin, 27, 551-562.
37. Wiersma, D., Nienhuis F. J., Slooff, C. J., et al (1998) Natural course of schizophrenia disorders: a 15-year follow-up of a Dutch incidence cohort. Schizophrenia Bulletin, 24, 75-85.
38. World Health Organization (2001) Mental Health Resources in the World: Report of Project Atlas. Geneva: World Health Organization.